Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 127

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 127
---
 Series C Preferred Stock (335,802 shares as of January 8, 2025); and                                           |

| ● | 1,345,679                                                                                                                                 
 shares of Common Stock issuable upon conversion of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred         
 Stock, including 497,977 shares issuable upon the exercise of Preferred Warrants (626,953 shares of Common Stock issuable upon conversion 
 of the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock as of January 8, 2025).                           |

71 DILUTION If you invest in the Common Stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering price per share of Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Offered Common Warrants, and the pro forma net tangible book value per share of Common Stock immediately after this offering. All information in this section has been presented giving retroactive effect to the Reverse Stock Split. As of September 30, 2024, our historical net negative tangible book value was $(3.7) million or $(2.48) per share of Common Stock. Historical net tangible book value per share of Common Stock represents our total tangible assets less total liabilities, divided by the number of shares of Common Stock outstanding as September 30, 2024. Giving effect to (i) the exercise of 2,462 Preferred Warrants for 2,462 shares of Series A Preferred Stock and the receipt of the cash proceeds of such exercises, (ii) the conversion of 3,484 shares of Series A Preferred Stock into 759,369 shares of Common Stock, including the shares of Series A Preferred Stock set forth in clause (i), (iii) the conversion of 213 shares of Series B Preferred Stock into 41,376 shares of Common Stock, and (iv) the issuance of 436,383 shares of Common Stock pursuant to the Keystone Equity Financing, in each case from October 1, 2024 through January 8, 2025, our as adjusted net tangible book would have been $357,000 or $0.13 per share of Common Stock. After giving effect to the receipt of the net proceeds from our sale of Common Stock in this offering at an assumed public offering price of $2.34 per share of Common Stock, assuming no sale of Pre-Funded Warrants in this offering and no exercise of Offered Common Warrants and after